34.99 +0.08 (0.23%)
After hours: 7:01PM EST
|Bid||34.85 x 1400|
|Ask||34.92 x 2900|
|Day's range||34.33 - 34.97|
|52-week range||31.43 - 43.18|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||35.19|
|Forward dividend & yield||2.11 (6.15%)|
|Ex-dividend date||18 Feb 2021|
|1y target est||N/A|
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.
Johnson & Johnson (NYSE: JNJ) recently won U.S. Emergency Use Authorization (EUA) for its vaccine. In this Motley Fool Live video, recorded on Feb. 24, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not Sanofi and GlaxoSmithKline might be too late to the party.
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today